LONIDAMINE IN MODULATION OF RESPONSE TO ADRIAMYCIN IN ADVANCED BREAST-CANCER - PRELIMINARY-RESULTS

A multicentric randomized clinical trial on advanced breast cancer pat ients has been designed in order to confirm the positive results of in vitro studies on the potentiation by lonidamine of the antiproliferat ive activity of adriamycin. This first report is based mainly on the a nalysis of toxicity on 85 patients who completed the planned therapeut ic program. Adriamycin toxicity did not differ much from that reported in the literature; some compliance difficulties were, however, report ed in a group of patients treated with lonidamine. This data, if confi rmed by final results, must be taken into consideration when the dose intensity and related clinical response are evaluated.